CTLA4 and non-small cell lung carcinoma: The same vaccine (CV9202 or BI1361849) has been evaluated in an open-label, multicenter, two-armed study (NCT03164772) to assess the safety and preliminary efficacy of adding the vaccine to one or two ICIs for NSCLC, namely, the anti-PD-L1 antibody durvalumab and the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody tremelimumab [34].